Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance
Open Access
- 10 October 2025
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 20 (3) , 629-636
Abstract
The detection of actionable mutations in liquid biopsies is a crucial tool for precision oncology in patients with non‐small‐cell lung cancer (NSCLC). We evaluated actionable alterations using a multigene panel in circulating tumor DNA (ctDNA) from Brazilian NSCLC patients. We analyzed 32 samples from 30 patients with NSCLC, including four samples from a lung cancer screening program. ctDNA isolation and library preparation were performed using the Oncomine Lung cfDNA Assay, which covers 11 actionable genes, and sequenced on an Ion S5 Sequencer. The IonReporter 5.20 software was used for variant calling. Median read coverage reached 80 967, with a detection limit of 0.1%. TP53 (40.6%) , KRAS (28.1%), and EGFR (12.5%) were the most frequently mutated genes, particularly in patients who had previously received treatment. BRAF, MAP2K1, PIK3CA, and ALK mutations were observed at lower frequencies (6.2%, 3.1%, 3.1%, and 3.1%, respectively). The EGFR p.T790M mutations related to resistance were identified in a patient who had been previously treated, and the TP53 p.R248Q mutation was discovered in an asymptomatic patient before diagnosis. No variants were observed in NRAS, ROS1, and MET genes. Our data showed that this commercial NGS panel could detect actionable mutations, enabling early detection, treatment monitoring, and disease surveillance.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2023/03918‐0; 2021/13861‐0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 11 references indexed in Scilit:
- Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene TestingThoracic Cancer, 2025
- Tumor biomarkers for diagnosis, prognosis and targeted therapySignal Transduction and Targeted Therapy, 2024
- Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung AdenocarcinomaPathobiology, 2023
- Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening ProgramsInternational Journal of Molecular Sciences, 2023
- Implementation of an Integrated Lung Cancer Prevention and Screening Program Using a Mobile Computed Tomography (CT) Unit in BrazilCancer Control, 2022
- Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutationsScientific Reports, 2019
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to DacomitinibJournal of Thoracic Oncology, 2018
- Tracking the Evolution of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006